Physician profile
Mark Downey
NPI 1477507648
$1,906.83
in general payments reported to CMS, 2019-2025
19 companies · $513 in 2025
The $513 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $211 · 2021: $185 · 2022: $96.12 · 2023: $176 · 2024: $542 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,231.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $514.59 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept, Infinion 16 |
| Abbott Laboratories | $380.47 | 2019-2025 | Proclaim |
| Nevro Corp. | $258.85 | 2020-2024 | Senza |
| Globus Medical, INC. | $188.01 | 2025 | Senza |
| Curonix LLC | $97.95 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Vertos Medical, INC. | $91.03 | 2021 | |
| Ibsa Pharma INC. | $59.15 | 2021-2023 | Tirosint, Licart |
| Si-Bone, INC. | $45.08 | 2020-2021 | |
| Baxter Healthcare | $38.94 | 2019 | |
| Saluda Medical Americas, INC. | $38.52 | 2023-2025 | Evoke Scs, Evoke |
| Stimwave Technologies Incorporated | $29.59 | 2019 | |
| Pfizer INC. | $28.22 | 2020-2021 | |
| Biotronik Nro, INC. | $26.94 | 2025 | Prospera |
| Kowa Pharmaceuticals America, INC. | $24.97 | 2022-2023 | Seglentis |
| Vertex Pharmaceuticals Incorporated | $22.26 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $21.32 | 2019 | |
| Avanos Medical | $17.05 | 2025 | Standard Rf Disposables |
| Horizon Therapeutics Plc | $13.05 | 2021 | |
| Zyla Life Sciences, INC. | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Downey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.